Proficio Capital Partners LLC Takes Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Proficio Capital Partners LLC bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 58,334 shares of the medical research company's stock, valued at approximately $10,768,000. Proficio Capital Partners LLC owned approximately 0.11% of Charles River Laboratories International as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter worth about $601,000. JPMorgan Chase & Co. lifted its position in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares in the last quarter. State Street Corp boosted its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Charles River Laboratories International by 3.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock valued at $22,060,000 after acquiring an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the company from $155.00 to $175.00 in a research note on Tuesday. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research report on Monday. Robert W. Baird dropped their target price on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group reduced their price target on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Finally, StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $198.36.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded down $0.12 during trading hours on Thursday, reaching $167.43. The company's stock had a trading volume of 415,954 shares, compared to its average volume of 693,472. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $275.00. The company's 50 day simple moving average is $170.06 and its 200 day simple moving average is $186.32. The stock has a market cap of $8.56 billion, a P/E ratio of 1,117.24, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the company posted $2.46 earnings per share. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).